georgeclerk

Atossa Therapeutics (NASDAQ:ATOS) traded higher on Monday after H.C. Wainwright launched its coverage with a Buy rating and a $4 per share target, citing the prospects of its lead asset, Z-Endoxifen, an active metabolite of the pro-drug Tamoxifen.

HCW analyst

End

To Get The Latest News Update

Sign up to Our Subscription.

We don’t spam! Read our privacy policy for more info.

To Get The Latest News Update

Sign up to Our Subscription.

We don’t spam! Read our privacy policy for more info.